At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating eribulin mesylate for Adenocarcinoma of the Prostate and 3 related conditions. Completed, enrolled 121 participants across 147 sites.
Detailed Summary
This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartNov 2006
Primary CompletionJun 2009
Study CompletionNov 2013
TodayJul 2026
First PostedJun 15, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2009
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.0 years ago
Interventions
eribulin mesylatedrug
Given IV